
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES65
When nateglinide in combination with metformin was compared with monotherapy of each treatment and placebo in drug naive patients with Type 2 diabetes: nateglinide, metformin and combination therapy (nateglinide + metformin), were associated with significant reductions in HbA1c, FPG and PPGE (an additive effect was seen with combination therapy)  the incidence of GI AEs was higher in patients receiving combination therapy and metformin than in those receiving placebo and nateglinide  the incidence of hypoglycaemic episodes was higher in the combination treatment group than in either of the monotherapy groups.

[@Ristic_2006]

